Updates in arteriovenous malformation management: the post-ARUBA era  

作　　者：James Feghali Judy Huang 

机构地区：[1]Department of Neurosurgery,Johns Hopkins University School of Medicine,Baltimore,Maryland,USA

出　　处：《Stroke & Vascular Neurology》2020年第1期34-39,共6页卒中与血管神经病学（英文）

摘　　要：Brain arteriovenous malformations(AVMs)are complex and heterogeneous lesions that can rupture,causing significant morbidity and mortality.While ruptured lesions are usually treated,the management of unruptured AVMs remains unclear.A Randomized trial of Unruptured Brain Arteriovenous Malformations(ARUBA)was the first trial conducted to compare the effects of medical and interventional therapy.Although it concluded that medical therapy was superior in preventing stroke and death over a follow-up period of 33 months,the findings were met with intense criticism regarding several aspects of study design,progression,and analysis/conclusion.Namely,the increased use of stand-alone embolisation relative to microsurgery in a cohort with predominantly low-grade lesions combined with a short follow-up period amplified treatment risk.Subsequently,several observational studies were conducted on ARUBA-eligible patients to investigate the safety and efficacy of microsurgery,radiosurgery,and endovascular embolisation over longer follow-up periods.These reports showed that favourable safety profiles and cure rates can be achieved with appropriate patient selection and judicious use of different treatment modalities in multidisciplinary centres.Since large prospective randomised trials on AVMs may not be feasible,it is important to make use of practice-based data beyond the flawed ARUBA study to optimise patients’lifetime outcomes.

关 键 词：treatment LIFETIME ALONE 

分 类 号：R743.4[医药卫生—神经病学与精神病学]